September 9th 2025
Zilebesiran’s twice-yearly dosing and sustained BP reductions could offer a new therapeutic approach for adults with resistant hypertension and high CV risk who are uncontrolled on current SOC regimens.
SuperWIN Trial of Retail-based Dietary Interventions Wins on Many Levels: Dylan Steen, MD, Explains
April 14th 2022Coprincipal investigator Steen highlights the first-of-its kind study and the findings—local in-store dietitian counseling/feedback, nutrition education, and online shopping savvy improve food choices, health metrics.